| Literature DB >> 25633363 |
Yang Wang1, Ling Zhang, Gen-Tao Li, Zheng-Hui Li, Ze-Jun Dong, Yan Li, Ji-Kai Liu.
Abstract
Engleromyces goetzii is a traditional medicinal mushroom that is widely used to treat infection, inflammation and cancer in Tibet, Sichuan and Yunnan provinces of China. Two new trichothecenes, engleromycones A and B (1 and 2), one new cuparane-type sesquiterpenoid named infuscol F (11), eight known trichothecene analogs, sambucinol (3), 3-deoxysambucinol (4), trichothecolone (5), trichodermol (6), 8-deoxytrichothecin (7), trichothecin (8), trichothecinol B (9) and trichothecinol A (10), and one known cyclopentanoid sesquiterpene cyclonerodiol (12) were isolated from the cultures of E. goetzii. The new compounds were elucidated through spectroscopic analyses. The anticancer effects of trichothecenes 1-10 were examined in the HL-60, SMMC-7721, A549, MCF-7, and SW-480 human cancer cell lines using an MTT assay. Trichothecinol A (10) significantly inhibited the growth of MCF-7 cells, with an IC50 value of 0.006 µM, which was comparable to the cytotoxic activity of the positive control, paclitaxel, indicating that trichothecinol A (10) represents a potential anticancer agent.Entities:
Year: 2015 PMID: 25633363 PMCID: PMC4328002 DOI: 10.1007/s13659-014-0051-1
Source DB: PubMed Journal: Nat Prod Bioprospect ISSN: 2192-2209
Fig. 1Structures of compounds 1–12
Fig. 2Selected 2D NMR correlations of 1
1H NMR (500 MHz) and 13C NMR (125 MHz) data for compounds 1 and 2 in CDCl3
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| 2 | 79.9, d | 4.42, d (5.1) | 79.3, d | 4.54, d (5.2) |
| 3 | 38.1, t | 2.63, dd (16.8, 7.7) | 37.9, t | 2.64, dd (15.6, 7.6) |
| 1.89, ddd (16.8, 5.1, 2.0) | 1.83, ddd (15.6, 5.2, 3.5) | |||
| 4 | 76.2, d | 5.32, dd (7.7, 2.0) | 73.4, d | 5.54, dd (7.6, 3.5) |
| 5 | 53.6, s | 51.7, s | ||
| 6 | 54.8, s | 43.6, s | ||
| 7 | 47.7, t | 2.74, d (15.0) | 41.6, t | 2.79, d (16.0) |
| 2.28, d (15.0) | 2.20, d (16.0) | |||
| 8 | 198.5, s | 199.5, s | ||
| 9 | 141.4, s | 138.0, s | ||
| 10 | 133.5, d | 6.40, overlapped | 137.3, d | 6.47, dd (5.7, 1.4) |
| 11 | 105.9, s | 69.6, d | 3.95, d (5.7) | |
| 12 | 96.7, s | 151.5, s | ||
| 13 | 58.6, t | 4.10, d (12.5) | 107.0, t | 5.22, s, H-b |
| 3.90, dd (12.5, 7.5) | 4.81, s, H-a | |||
| 14 | 10.9, q | 0.91, s | 10.0, q | 0.93, s |
| 15 | 17.4, q | 1.08, s | 18.4, q | 1.05, s |
| 16 | 15.4, q | 1.84, s | 15.5, q | 1.78, s |
| 1′ | 165.2, s | 165.9, s | ||
| 2′ | 119.7, d | 5.74, dd (11.4, 1.8) | 120.2, d | 5.76, dd (11.4, 1.8) |
| 3′ | 146.9, d | 6.40, overlapped | 146.1, d | 6.36, dq (11.4, 7.4) |
| 4′ | 15.4, q | 2.14, dd (7.2, 1.8) | 15.5, q | 2.13, dd (7.4, 1.8) |
| 13-OH | 2.01, brs | |||
Fig. 3Selected 2D NMR correlations of 2
Fig. 4Selected 2D NMR correlations of 11
Inhibitory effect of the isolated compounds against different cancer cell lines
| Compd. | Cancer cell line IC50 (μM) | ||||
|---|---|---|---|---|---|
| HL-60 | SMMC-7721 | A549 | MCF-7 | SW480 | |
|
| 14.29 | 19.12 | 19.10 | 18.04 | 20.22 |
|
| 2.70 | 8.41 | 2.98 | 21.13 | 9.25 |
|
| >40 | >40 | >40 | >40 | >40 |
|
| >40 | >40 | >40 | >40 | >40 |
|
| 4.86 | 6.92 | 4.16 | 16.49 | 8.52 |
|
| 1.53 | 2.14 | 1.01 | 3.43 | 1.87 |
|
| 0.10 | 0.15 | 0.14 | 0.23 | 0.15 |
|
| 0.14 | 0.22 | 0.20 | 0.21 | 0.18 |
|
| 1.68 | 0.45 | 0.40 | 0.54 | 0.35 |
|
| 0.022 | 0.020 | 0.015 | 0.006 | 0.011 |
| Cisplatin | 1.91 | 5.81 | 6.43 | 13.26 | 11.99 |
| Taxol | <0.008 | <0.008 | <0.008 | <0.008 | <0.008 |
Inhibitory effect of compounds 1, 2 and 5–10 against A-549 and BEAS-2B cell Lines
| Compd. | Cancer cell line IC50 (μM) | |
|---|---|---|
| A549 | BEAS-2B | |
|
| 18.94 | 19.42 |
|
| 5.82 | 9.87 |
|
| 5.71 | 4.18 |
|
| 1.54 | 1.06 |
|
| 0.15 | 0.11 |
|
| 0.22 | 0.27 |
|
| 0.56 | 0.45 |
|
| 0.016 | 0.025 |
| Cisplatin | 9.72 | 9.53 |
| Paclitaxel | <0.008 | <0.98 |
1HNMR (600 MHz) and 13C NMR (150 MHz) data for compound 11 in acetone-d 6
|
|
| |
|---|---|---|
| 1 | 25.8, t | 2.31, m, H-α |
| 1.96, m, H-β | ||
| 2 | 33.8, t | 1.73, ddd (12.8, 6.9, 5.4) |
| 1.48, overlapped | ||
| 3 | 69.2, s | |
| 4 | 72.2, d | 3.74, m |
| 5 | 123.8, d | 5.44, m |
| 6 | 146.0, s | |
| 7 | 51.4, s | |
| 8 | 37.4 t | 2.17, m, H-β |
| 1.41, m, H-α | ||
| 9 | 19.7, t | 1.62, overlapped |
| 10 | 41.0, t | 1.62, overlapped |
| 1.49, overlapped | ||
| 11 | 44.3, s | |
| 12 | 25.1, q | 1.02, s |
| 13 | 26.4, q | 0.79, s |
| 14 | 22.7, q | 0.99, s |
| 15 | 25.4, q | 1.13, s |